|
Market Closed -
Swiss Exchange
20:31:52 16/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 135.76 CHF | +1.27% |
|
+1.72% | +23.87% |
| 08:20am | Novartis' Polymyalgia Rheumatica Drug Wins US FDA Nod | MT |
| 07:50am | Novartis Announces FDA Approval of Cosentyx for Treatment of Polymyalgia Rheumatica | CI |
Company Valuation: Novartis AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 196,458 | 194,448 | 207,167 | 195,514 | 266,003 | 305,452 | - | - |
| Change | - | -1.02% | 6.54% | -5.62% | 36.05% | 14.83% | - | - |
| Enterprise Value (EV) 1 | 204,649 | 203,482 | 219,178 | 213,458 | 289,870 | 339,006 | 333,796 | 327,487 |
| Change | - | -0.57% | 7.71% | -2.61% | 35.8% | 16.95% | -1.54% | -1.89% |
| P/E | 8.2x | 28.3x | 14.1x | 16.5x | 19.2x | 24.4x | 19.1x | 16.9x |
| PBR | 2.9x | 3.23x | 4.41x | 4.52x | 5.73x | 6.95x | 6.34x | 5.66x |
| PEG | - | -0.4x | 0x | -1x | 0.9x | -3.01x | 0.7x | 1.3x |
| Capitalization / Revenue | 3.81x | 3.85x | 4.44x | 3.78x | 4.69x | 5.29x | 4.95x | 4.67x |
| EV / Revenue | 3.96x | 4.03x | 4.7x | 4.13x | 5.11x | 5.87x | 5.41x | 5x |
| EV / EBITDA | 11.2x | 10.9x | 12.2x | 10.2x | 12.4x | 14.3x | 13x | 12x |
| EV / EBIT | 12.3x | 12.2x | 13.4x | 10.9x | 13.2x | 15.1x | 13.9x | 12.7x |
| EV / FCF | 15.4x | 17x | 16.6x | 13.1x | 16.5x | 22.3x | 18.3x | 16.4x |
| FCF Yield | 6.49% | 5.87% | 6.01% | 7.61% | 6.07% | 4.48% | 5.46% | 6.09% |
| Dividend per Share 2 | 3.36 | 3.5 | 3.823 | 3.856 | 4.762 | 4.372 | 4.591 | 4.764 |
| Rate of return | 3.83% | 3.87% | 3.79% | 3.94% | 3.44% | 2.7% | 2.84% | 2.95% |
| EPS 2 | 10.71 | 3.19 | 7.15 | 5.92 | 7.21 | 6.625 | 8.476 | 9.554 |
| Distribution rate | 31.4% | 110% | 53.5% | 65.1% | 66% | 66% | 54.2% | 49.9% |
| Net sales 1 | 51,626 | 50,545 | 46,660 | 51,722 | 56,674 | 57,754 | 61,699 | 65,452 |
| EBITDA 1 | 18,246 | 18,613 | 17,937 | 21,006 | 23,415 | 23,745 | 25,608 | 27,365 |
| EBIT 1 | 16,588 | 16,665 | 16,372 | 19,494 | 21,889 | 22,385 | 24,024 | 25,843 |
| Net income 1 | 24,021 | 6,955 | 14,854 | 11,939 | 13,967 | 12,747 | 15,683 | 17,433 |
| Net Debt 1 | 8,191 | 9,034 | 12,011 | 17,944 | 23,867 | 33,554 | 28,343 | 22,035 |
| Reference price 2 | 87.82 | 90.40 | 100.79 | 97.79 | 138.63 | 161.73 | 161.73 | 161.73 |
| Nbr of stocks (in thousands) | 2,237,092 | 2,150,980 | 2,055,460 | 1,999,270 | 1,918,792 | 1,888,624 | - | - |
| Announcement Date | 02/02/22 | 01/02/23 | 31/01/24 | 31/01/25 | 04/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 24x | 5.82x | 14.17x | 2.73% | 305B | ||
| 42.25x | 14.3x | 30.31x | 0.47% | 1,275B | ||
| 41.82x | 7.01x | 19.73x | 1.87% | 680B | ||
| 37.62x | 8.63x | 17.81x | 2.34% | 521B | ||
| 21.75x | 5.27x | 13.2x | 2.48% | 389B | ||
| 104.88x | 5.98x | 25.49x | 2.3% | 356B | ||
| 24.25x | 4.85x | 13.63x | 1.8% | 287B | ||
| 24.04x | 7.38x | 13.56x | 2.17% | 250B | ||
| -39.41x | 7.29x | 45.94x | 1.97% | 208B | ||
| 12.07x | 4.33x | 8.9x | 4.08% | 185B | ||
| Average | 29.33x | 7.09x | 20.27x | 2.22% | 446B | |
| Weighted average by Cap. | 36.36x | 8.75x | 22.08x | 1.78% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- NOVN Stock
- Valuation Novartis AG
Select your edition
All financial news and data tailored to specific country editions
















